Leveder 500 Tablet contains Levetiracetam 500 mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. It is commonly prescribed as adjunctive therapy but may also be used as monotherapy depending on clinical judgment. The medication is well-absorbed orally with rapid onset of action and is primarily eliminated unchanged via the kidneys, necessitating dose adjustments in patients with renal impairment. Leveder 500 Tablet is generally well-tolerated; common adverse effects include somnolence, dizziness, headache, and fatigue. Serious adverse reactions are rare but may include behavioral changes or hypersensitivity reactions. Regular monitoring of clinical response and renal function is recommended during therapy. Patients should be advised to adhere strictly to prescribed dosing schedules and not discontinue treatment abruptly to avoid seizure exacerbation. Leveder 500 Tablet should be used under medical supervision, with caution in populations such as pregnant or breastfeeding women, and those with a history of psychiatric illness.